Website & contact details
- Website
Molecule Hyperdrug Ltd
- Incorporated
- 21 March 1985 (41 years)
- Previously known as
- Hyperdrug Pharmaceuticals Ltd (until 25 September 2026)Hyperdrug Limited (until 11 September 2002)
- Industry
- Manufacture of pharmaceutical preparations (21200) Dispensing chemist in specialised stores (47730)Veterinary activities (75000)
- Directors
- Brendan Celestine O'Brien
- Owned by
- Molecule Pharmacy Ltd
- Accounts type
- Total exemption full
- Region
- Greater London
- Address
- 201 Temple Chambers 3-7 Temple AvenueLondonEC4Y 0DT
Filing status
- Accounts due
- 31 December 2026
- Last accounts
- 30 April 2025
- Conf. stmt due
- 12 January 2027
- Last conf. stmt
- 29 December 2025
Charges
- Total
- 1
- Outstanding
- 0
- Part satisfied
- 0
- Satisfied
- 1
Officers 3 active
Officer details are public data from the Companies House register.
Director · Appointed 19 March 2026
British
Born December 1962 (63)
Director · Appointed 19 March 2026
British
Born October 1957 (69)
O'Brien, Brendan Celestine
Director · Appointed 19 March 2026
Irish
Born March 1968 (58)
Officer history (5 former)
19 March 2026
19 March 2026
19 March 2026
Appointed O'Brien, Brendan Celestine as Director
19 March 2026
Resigned Watson, Benjamin Nicholas as Director
19 March 2026
Resigned Watson, John Geoffrey Frederick as Director
19 March 2026
Resigned Watson, Christine Jennifer as Secretary
19 March 2026
Resigned Watson, Christine Jennifer as Director
19 March 2026
23 November 2006
Appointed Watson, Benjamin Nicholas as Director
1 January 1996
Appointed Watson, John Geoffrey Frederick as Director
Ownership 1 active
People and entities with significant control, from the Companies House PSC register
Molecule Pharmacy Ltd
Corporate entity · Notified 19 March 2026
Owns 75–100% of shares
Holds 75–100% of voting rights
Right to appoint and remove directors
Private Limited Company
Former controllers (2)
19 March 2026
19 March 2026
Ceased Christine Jennifer Watson — Owns 25–50% of shares
Financials
Balance sheet as at 30 April 2025 · total exemption full accounts
- Net Assets
- £227,551
- Cash
- £767,976
- Employees
- 25
- Debt Ratio
- 84%
- Current Ratio
- 1.0x
Trend
Net Assets
Balance sheet detail
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Fixed Assets | £270,607 | £292,920 | £400,369 | £423,860 | £450,835 | |
| Current Assets | £1,117,423 | £1,179,663 | £1,819,539 | £1,736,659 | £1,896,398 | |
| Debtors | £91,848 | £73,940 | £32,401 | £20,437 | £86,830 | |
| Cash | £767,976 | £755,296 | £1,330,368 | £1,275,306 | £1,346,025 | |
| Creditors (< 1 year) | £1,082,326 | £1,176,305 | £1,351,807 | £1,619,338 | £1,450,936 | £1,744,980 |
| Creditors (> 1 year) | £50,404 | £50,404 | £100,000 | £100,000 | £100,000 | £100,000 |
| Net Current Assets | £35,097 | £3,358 | £200,201 | £285,723 | £151,418 | |
| Net Assets | £227,551 | £215,048 | £447,656 | £566,975 | £454,266 | |
| Shareholder Funds | £227,551 | £215,048 | £447,656 | £566,975 | £454,266 |
What Molecule Hyperdrug say about themselves
“Molecule brings together clinic, pharmacy and veterinary care: prescriptions, medicines and expert advice for people and their animals, from one trusted UK-regulated group.”
Filings
Recent filings only. See the full history on Companies House
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 22 October 2026 | Change of details for a person with significant control | |||
| 29 May 2026 | Memorandum and Articles of Association | |||
| 12 May 2026 | Resolutions | |||
| 7 May 2026 | Cessation of a person with significant control | |||
| 7 May 2026 | Cessation of a person with significant control |
Some other companies at this address
Other companies in this industry
Runcorn
Northampton
Oxford
Castleford
By trade and location
Explore the largest companies
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →